BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38285090)

  • 1. Sphingomyelin synthase 2 promotes the stemness of breast cancer cells via modulating NF-κB signaling pathway.
    Feng H; Dong Y; Chen K; You Z; Weng J; Liang P; Shi F
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):46. PubMed ID: 38285090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingomyelin Synthase 2 Inhibition Ameliorates Cerebral Ischemic Reperfusion Injury Through Reducing the Recruitment of Toll-Like Receptor 4 to Lipid Rafts.
    Xue J; Yu Y; Zhang X; Zhang C; Zhao Y; Liu B; Zhang L; Wang L; Chen R; Gao X; Jiao P; Song G; Jiang XC; Qin S
    J Am Heart Assoc; 2019 Nov; 8(22):e012885. PubMed ID: 31718447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
    Ku JM; Kim SR; Hong SH; Choi HS; Seo HS; Shin YC; Ko SG
    Mol Cell Biochem; 2015 Nov; 409(1-2):33-43. PubMed ID: 26169986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
    Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
    Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
    Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
    Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
    [No Abstract]   [Full Text] [Related]  

  • 6. Deficiency of sphingomyelin synthase 2 prolongs survival by the inhibition of lymphoma infiltration through ICAM-1 reduction.
    Taniguchi M; Ueda Y; Matsushita M; Nagaya S; Hashizume C; Arai K; Kabayama K; Fukase K; Watanabe K; Wardhani LO; Hayashi K; Okazaki T
    FASEB J; 2020 Mar; 34(3):3838-3854. PubMed ID: 31970839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice.
    Liu J; Huan C; Chakraborty M; Zhang H; Lu D; Kuo MS; Cao G; Jiang XC
    Circ Res; 2009 Jul; 105(3):295-303. PubMed ID: 19590047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
    Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
    BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
    Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
    Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baicalin Antagonizes Prostate Cancer Stemness via Inhibiting Notch1/NF-κB Signaling Pathway.
    Wu MH; Wu K; Zhu YB; Li DC; Yang H; Zeng H
    Chin J Integr Med; 2023 Oct; 29(10):914-923. PubMed ID: 37357241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression.
    Li Y; Dong J; Ding T; Kuo MS; Cao G; Jiang XC; Li Z
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1513-20. PubMed ID: 23640498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of PIMREG promotes breast cancer aggressiveness via constitutive activation of NF-κB signaling.
    Jiang L; Ren L; Zhang X; Chen H; Chen X; Lin C; Wang L; Hou N; Pan J; Zhou Z; Huang H; Huang D; Yang J; Liang Y; Li J
    EBioMedicine; 2019 May; 43():188-200. PubMed ID: 30979686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sphingomyelin synthase 2 deficiency decreases atherosclerosis and inhibits inflammation in mice].
    Qin R; Chen ML; Zhu K; Deng JB; Shi YY
    Sheng Li Xue Bao; 2010 Aug; 62(4):333-8. PubMed ID: 20717634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20(S)-ginsenoside Rh2.
    Zhang J; Lu M; Zhou F; Sun H; Hao G; Wu X; Wang G
    Drug Metab Dispos; 2012 Oct; 40(10):1900-8. PubMed ID: 22745335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SENP2 suppresses NF-κB activation and sensitizes breast cancer cells to doxorubicin.
    Gao X; Wu Y; Qiao L; Feng X
    Eur J Pharmacol; 2019 Jul; 854():179-186. PubMed ID: 30940449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
    Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
    J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eugenol potentiates cisplatin anti-cancer activity through inhibition of ALDH-positive breast cancer stem cells and the NF-κB signaling pathway.
    Islam SS; Al-Sharif I; Sultan A; Al-Mazrou A; Remmal A; Aboussekhra A
    Mol Carcinog; 2018 Mar; 57(3):333-346. PubMed ID: 29073729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective sphingomyelin synthase 2 inhibitor ameliorates diet induced insulin resistance
    Huang Y; Huang T; Zhen X; Li Y; Mo M; Ye D; Cheng N
    Pharmazie; 2019 Sep; 74(9):553-558. PubMed ID: 31484596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camel Urine Promotes Sensitization to Doxorubicin by Inhibiting Epithelial-Mesenchymal Transition and Modulating NF-κB-Snail Signaling Pathway in Breast Cancer Cells.
    Al-Mutairi MS; Matar IK; Alfadli S; Al-Mutairi A
    Asian Pac J Cancer Prev; 2021 Dec; 22(12):4017-4029. PubMed ID: 34967584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells.
    Abdin SM; Tolba MF; Zaher DM; Omar HA
    Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.